New monoclonal antibody safe and effective for rare liver disease

HealthIANS
Advertisement
New Delhi, Dec 24 : A new monoclonal antibody treatment has shown promising results for a rare liver disease called primary sclerosing cholangitis (PSC).

The team from the University of California-Davis, US, tested an anti-inflammatory and anti-fibrotic monoclonal antibody known as nebokitug and found it to be safe and potentially effective in patients with PSC.

Published in the American Journal of Gastroenterology, the results offer encouraging news for patients with PSC, for which there are currently no effective treatments short of liver transplantation.

"In the trial, nebokitug demonstrated that it has the potential to change the lives of patients with PSC by reducing fibrosis and inflammation, which should lead to improved outcomes," said Christopher Bowlus, chief of Gastroenterology and Hepatology at UC Davis Health.

"These results are good news for patients with PSC, who are in desperate need of an effective, FDA-approved therapy."

PSC is a rare, chronic liver disease that causes inflammation and scarring of the bile ducts. These ducts carry bile from the liver to the small intestine to help digest fats. When they become damaged and narrow, bile builds up in the liver, leading to liver injury over time.

The exact cause of PSC is not fully understood, but most patients also have inflammatory bowel disease, suggesting a direct link between intestinal inflammation and the liver.

Symptoms can include fatigue, itching, and jaundice, though some people have no symptoms at first. There is no cure, and treatment focuses on managing symptoms and complications. In advanced cases, a liver transplant may be needed.

Nebokitug is a lab-made antibody designed to block a protein called CCL24. This protein plays a role in inflammation and scarring by interacting with certain inflammatory cells in the liver.

In PSC, CCL24 levels are higher than normal and are found around the bile ducts, where they contribute to liver damage. Studies have shown that blocking CCL24 can reduce these harmful processes.

For the Phase 2 trial, 76 PSC patients across five countries were randomly assigned to receive nebokitug at two different doses or a placebo through an IV every three weeks for 15 weeks. The main goal was to check safety.

Results showed nebokitug was safe and well-tolerated. Patients, especially those with more advanced liver scarring, had improvements in key measures like liver stiffness and fibrosis markers compared to placebo.

Advertisement

Note: The content of this article is sourced from a news agency and has not been edited by the ap7am team.

Primary Sclerosing CholangitisPSCliver diseasenebokitugmonoclonal antibodyChristopher BowlusUC Davis Healthliver transplantCCL24

More News

Telangana’s 4,000 MW Yadadri plant to achieve full capacity soon

17 Nov, 19:01

Reports of unwanted Instagram recommendations in India halved over past year: Meta

17 Nov, 19:00

Trump watches as PM Modi picks up Indian flag marker from floor, video goes viral

17 Nov, 18:58

Rajinikanth's daughter Soundarya shares pictures of their family getaway in Greece; says 'What amazing memories we’ve made in Athens!'

17 Nov, 18:56

When Jackie Shroff gave 10x returns to Archana Puran Singh on pending principal amount from struggling days

17 Nov, 18:54

'There was no one like Dhoni, and can't see anyone in next 10 years either': Coach MP Singh

17 Nov, 18:53

Dulquer Salmaan's 'Aakasamlo Oka Tara' cleared for release with U/A certificate

17 Nov, 18:52

Gas leak from ONGC well in Andhra brought under control

17 Nov, 18:50

‘Learned the meaning of simplicity…’: Ruturaj Gaikwad’s heartfelt tribute to Dhoni

17 Nov, 18:49

Dhanush, Mammootty-starrer 'Om' cleared for release with U/A certificate!

17 Nov, 18:47

Sri Lanka lose 15 WTC points, Pakistan docked five for slow over-rate during Rawalpindi Test

17 Nov, 18:46

'IPL will not be the same': Cricket fraternity pays emotional tribute to MS Dhoni after retirement

17 Nov, 18:44

Rahul Gandhi responds to backlash over 'lap' remark, shares temple sculpture

17 Nov, 18:43

PM Modi is 'a very tough man': Trump after meeting Quad counterparts

17 Nov, 17:06

Drug cartels turn to private players, DIY videos to evade crackdown; agencies flag new trend

17 Nov, 17:05

Gurnoor Brar reprimanded for Code of Conduct breach, handed one demerit point

17 Nov, 17:03

Why did Telangana find no mention in Sonia Gandhi’s book: BRS

17 Nov, 17:02

MS Dhoni’s IPL legacy: Five titles, 5,439 runs and several records

17 Nov, 16:57

Nifty hits 9-month high, Bank Nifty scales record peak as market rally extends

17 Nov, 16:00

Dhoni quietly said, ‘Maybe you should add my name' in release list, reveals CSK owner Rupa Gurunath

17 Nov, 15:46
..More News